BiomXPHGE
PHGE
0
Funds holding %
of 7,390 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
20% more funds holding
Funds holding: 15 [Q3] → 18 (+3) [Q4]
4.73% more ownership
Funds ownership: 50.59% [Q3] → 55.32% (+4.73%) [Q4]
21% less capital invested
Capital invested by funds: $9.24M [Q3] → $7.32M (-$1.92M) [Q4]
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
100% less funds holding in top 10
Funds holding in top 10: 1 [Q3] → 0 (-1) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$2
251%
upside
Avg. target
$2
251%
upside
High target
$2
251%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Joseph Pantginis 21% 1-year accuracy 89 / 415 met price target | 251%upside $2 | Buy Reiterated | 10 Jan 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
5 days ago
BiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program Updates
NESS ZIONA, Israel, March 25, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE, the “Company” or “BiomX”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided program and business updates.
Neutral
GlobeNewsWire
1 week ago
BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025
NESS ZIONA, Israel, March 19, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will report fourth quarter and full year 2024 financial results and provide business and program updates on Tuesday, March 25, 2025.
Neutral
Seeking Alpha
4 months ago
BiomX Inc. (PHGE) Q3 2024 Earnings Call Transcript
BiomX Inc. (NYSE:PHGE ) Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ET Company Participants Marina Wolfson – Chief Financial Officer Jonathan Solomon – Chief Executive Officer Conference Call Participants Sara Nik – H.C. Wainwright Operator Greetings, and welcome to the BiomX Third Quarter 2024 Financial Results Conference Call.
Neutral
GlobeNewsWire
4 months ago
BiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program Updates
BX211 Phase 2 for treatment of Diabetic Foot Osteomyelitis (DFO) patient enrollment completed and on track to report topline results in Q1 2025
Neutral
GlobeNewsWire
4 months ago
BiomX to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 14, 2024
NESS ZIONA, Israel, Nov. 12, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Thursday, November 14, 2024, at 8:00 a.m. ET, to report third quarter 2024 financial results and provide business and program updates.
Neutral
GlobeNewsWire
5 months ago
BiomX Announces a Mandatory Unit Separation
GAITHERSBURG, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announces a mandatory separation of its units, which trade under the ticker symbol “PHGE.U”, each of which consists of one share of Common Stock and one warrant to purchase one-half of a share of Common Stock (the “Units”). Each warrant (a “Warrant”) entitles the holder to purchase one-half of a share of Common Stock at price of $115 per share.
Positive
Zacks Investment Research
6 months ago
BiomX Stock Gains From Favorable Study Data Presentation on BX004
PHGE is set to present data from its Phase 1b/2a study for BX004 at the North American Cystic Fibrosis Conference in Boston on Sept. 27 and Sept.
Neutral
GlobeNewsWire
6 months ago
BiomX to Provide Latest Update on Positive Phase 1b/2a Clinical Trial Data for BX004 at the North American Cystic Fibrosis Conference
GAITHERSBURG, Md., Sept. 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announces the Company will present further data from BiomX's Phase 1b/2a study of BX004 for the treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa pulmonary infections.
Neutral
GlobeNewsWire
6 months ago
BiomX to Present at the H.C. Wainwright 26th Annual Global Investment Conference
GAITHERSBURG, Md., Sept. 04, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, announces today that Jonathan Solomon, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 26th Annual Global Investment Conference. The conference is being held on September 9 - 11, 2024 at the Lotte New York Palace Hotel.
Neutral
GlobeNewsWire
7 months ago
UPDATE ON UNITS - BiomX Inc. Announces 1-for-10 Reverse Stock Split
In a release issued under the same headline yesterday by BiomX (NYSE American: PHGE), the third and fourth paragraphs have been updated to include information regarding adjustment of outstanding units following the reverse stock split
Charts implemented using Lightweight Charts™